Skip to content

    Fibromyalgia Health Center

    Font Size

    FDA Panel Rejects Xyrem as Fibromyalgia Treatment

    Advisory Panel Members Worry About Potential for Abuse of Drug That's Similar to GHB
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    Aug. 20, 2010 -- An FDA advisory panel today overwhelmingly rejected the application of Jazz Pharmaceuticals for the approval sodium oxybate (Xyrem) for the treatment of fibromyalgia.

    The drug is chemically similar to GHB, widely considered a date-rape drug. Approving it for such a large patient population -- 5 million people are estimated to suffer from fibromyalgia -- would risk flooding the streets with a pharmaceutical-grade version of the highly controlled substance.

    "Sodium oxybate and GHB are the same thing," said panelist Lewis Nelson, MD, of the New York University School of Medicine. "This is much better than the stuff you get on the street, and that is the problem."

    Currently, the drug is only approved for the treatment of narcolepsy. It has been prescribed for 35,000 people since it was introduced in 2002.

    "When drugs like GHB get out there, we wish it hadn't happened," said Thomas Kosten, MD, a Baylor University professor of psychiatry and addiction.

    Risks vs. Benefits

    Kosten, who vociferously opposed approval, also cited a lack of convincing evidence by the drugmaker that the risks involved in releasing the drug to such a large population were balanced by its effectiveness in treating fibromyalgia-related pain and sleeping problems, the two conditions for which Jazz was seeking approvals.

    "Without any data to show that this is better than existing medications, I think we are foolish to consider approving this drug," Kosten said in the discussion immediately preceding the vote.

    The panel's vote contrasted with the FDA's view of the data provided by Jazz, which included two studies measuring pain relief, and another study that tested its effectiveness as a sleep aid.

    "The agency agrees that there is evidence of efficacy" for treating pain, said FDA statistician David Petullo, MS, who reviewed the studies. The FDA did not, however, accept Jazz's claims that sodium oxybate had a positive effect on sleep.

    In the public comment period, the majority of the speakers supported approval of the drug. Many of them had participated in the Jazz-run studies. They explained, often emotionally, how much they had benefited from sodium oxybate after failing to respond to any of the three drugs approved to treat fibromyalgia.

    As many as 50% of those with the disease do not respond to available medications, said Jon Russell, MD, director of the University Clinical Research Center at the University of Texas Health Science Center at San Antonio, who spoke on behalf of Jazz.

    "We need more options for the care of fibromyalgia patients," said Russell, "and those should have different mechanisms of action."

    Today on WebMD

    instructor training woman with dumbbells
    Can it help your fibromyalgia flare-ups?
    woman painting
    It’s hard, but we’ve got tips.
    woman at desk rubbing shoulder
    Tips to modify your workspace is one step.
    Woman rubbing her upper back
    Get treatment options and coping skills.
    Fatigue or Something More
    Woman with stressed, fatigue
    woman in pain
    woman eating apple
    Sex Advice for Single Women
    Your Symptoms
    Uncomfortable mature woman